Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 34

  • Showing results for 2010[pdat] AND once-daily bronchodilators for chronic obstructive pulmonary disease. Your search for 2010[pdat] AND Once-Daily Bronchodilators for Chronic Obstructive Pulmonary Diseas retrieved no results.

Aclidinium bromide improves exercise endurance and lung hyperinflation in patients with moderate to severe COPD.

Maltais F, Celli B, Casaburi R, Porszasz J, Jarreta D, Seoane B, Caracta C.

Respir Med. 2011 Apr;105(4):580-7. doi: 10.1016/j.rmed.2010.11.019. Epub 2010 Dec 22.


Tiotropium increases cytosolic muscarinic M3 receptors and acetylated H3 histone proteins in induced sputum cells of COPD patients.

Holownia A, Mroz RM, Skopinski T, Kielek A, Kolodziejczyk A, Chyczewska E, Braszko JJ.

Eur J Med Res. 2010 Nov 4;15 Suppl 2:64-7.


Cardiovascular safety of QVA149, a combination of Indacaterol and NVA237, in COPD patients.

Van de Maele B, Fabbri LM, Martin C, Horton R, Dolker M, Overend T.

COPD. 2010 Dec;7(6):418-27. doi: 10.3109/15412555.2010.528812.


Bronchodilatory effects of NVA237, a once daily long-acting muscarinic antagonist, in COPD patients.

Fogarty C, Hattersley H, Di Scala L, Drollmann A.

Respir Med. 2011 Mar;105(3):337-42. doi: 10.1016/j.rmed.2010.10.021. Epub 2010 Dec 8.


Population pharmacodynamic model of the longitudinal FEV1 response to an inhaled long-acting anti-muscarinic in COPD patients.

Wu K, Looby M, Pillai G, Pinault G, Drollman AF, Pascoe S.

J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):105-19. doi: 10.1007/s10928-010-9180-2. Epub 2010 Nov 20.


Tiotropium Respimat® improves physical functioning in chronic obstructive pulmonary disease.

Rau-Berger H, Mitfessel H, Glaab T.

Int J Chron Obstruct Pulmon Dis. 2010 Oct 10;5:367-73.


[Indacaterol is a new once-daily beta2-agonist for treatment of COPD].

Ulrik CS.

Ugeskr Laeger. 2010 Nov 22;172(47):3260-3. Review. Danish.


An update on the use of indacaterol in patients with COPD.

Brienza NS, Amor-Carro O, Ramos-Barbón D.

Ther Adv Respir Dis. 2011 Feb;5(1):29-40. doi: 10.1177/1753465810387810. Epub 2010 Nov 8. Review.


Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current and future agents.

Tashkin DP, Fabbri LM.

Respir Res. 2010 Oct 29;11:149. doi: 10.1186/1465-9921-11-149. Review.


[A randomized, double-blind, placebo-control study of once-daily inhaled tiotropium in chronic obstructive pulmonary disease].

Yin KS, Zhang DP, Shi Y, Sun LH, Min R, Xiao YL, Xia XR, Tan Y, Fu WZ.

Zhonghua Jie He He Hu Xi Za Zhi. 2010 Jul;33(7):519-23. Chinese.


QVA149 demonstrates superior bronchodilation compared with indacaterol or placebo in patients with chronic obstructive pulmonary disease.

van Noord JA, Buhl R, Laforce C, Martin C, Jones F, Dolker M, Overend T.

Thorax. 2010 Dec;65(12):1086-91. doi: 10.1136/thx.2010.139113. Epub 2010 Oct 26.


Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium.

Vogelmeier C, Ramos-Barbon D, Jack D, Piggott S, Owen R, Higgins M, Kramer B; INTIME study investigators (INdacaterol & TIotropium: Measuring Efficacy).

Respir Res. 2010 Oct 5;11:135. doi: 10.1186/1465-9921-11-135.


Onset of action of indacaterol in patients with COPD: comparison with salbutamol and salmeterol-fluticasone.

Balint B, Watz H, Amos C, Owen R, Higgins M, Kramer B; INSURE Study Investigators.

Int J Chron Obstruct Pulmon Dis. 2010 Sep 7;5:311-8.


Inhalation by design: novel ultra-long-acting β(2)-adrenoreceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulfonamide agonist headgroup.

Glossop PA, Lane CA, Price DA, Bunnage ME, Lewthwaite RA, James K, Brown AD, Yeadon M, Perros-Huguet C, Trevethick MA, Clarke NP, Webster R, Jones RM, Burrows JL, Feeder N, Taylor SC, Spence FJ.

J Med Chem. 2010 Sep 23;53(18):6640-52. doi: 10.1021/jm1005989.


Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.

Kornmann O, Dahl R, Centanni S, Dogra A, Owen R, Lassen C, Kramer B; INLIGHT-2 (Indacaterol Efficacy Evaluation Using 150-µg Doses with COPD Patients) study investigators.

Eur Respir J. 2011 Feb;37(2):273-9. doi: 10.1183/09031936.00045810. Epub 2010 Aug 6.


Indacaterol maleate for the treatment of chronic obstructive pulmonary disease.

Tashkin DP.

Expert Opin Pharmacother. 2010 Aug;11(12):2077-85. doi: 10.1517/14656566.2010.499358. Review.


A one-year trial of tiotropium Respimat plus usual therapy in COPD patients.

Bateman ED, Tashkin D, Siafakas N, Dahl R, Towse L, Massey D, Pavia D, Zhong NS.

Respir Med. 2010 Oct;104(10):1460-72. doi: 10.1016/j.rmed.2010.06.004.


Effects of tiotropium and formoterol on dynamic hyperinflation and exercise endurance in COPD.

Berton DC, Reis M, Siqueira AC, Barroco AC, Takara LS, Bravo DM, Andreoni S, Neder JA.

Respir Med. 2010 Sep;104(9):1288-96. doi: 10.1016/j.rmed.2010.05.017. Epub 2010 Jun 26.

Supplemental Content

Loading ...
Support Center